Literature DB >> 4447775

Delayed cutaneous hypersensitivity reactions in patients with Kaposi's sarcoma.

J F Taylor, J L Ziegler.   

Abstract

Defects in cellular immunocompetence have been sought in 25 patients with Kaposi's sarcoma. Skin tests with recall antigens, and PHA lymphocyte stimulation in vitro showed that efferent delayed hypersensitivity responses are intact in the majority. However, attempted sensitization and subsequent challenge with DNCB demonstrated that the afferent limb of the responses was impaired in some patients. This did not appear to be related to the morphology of the tumour or to prognosis.Tumour specific reactions were demonstrated both in vivo and in vitro and these correlated significantly with the morphology and histology. The interpretation of the results for an individual is confounded by the multiplicity of factors influencing the outcome in a particular patient.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4447775      PMCID: PMC2009295          DOI: 10.1038/bjc.1974.198

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Immune deficiencies and Kaposi's sarcoma.

Authors:  A Dobozy; S Husz; J Hunyadi; G Berkó; N Simon
Journal:  Lancet       Date:  1973-09-15       Impact factor: 79.321

3.  Immunological studies in Kaposi's sarcoma in Uganda.

Authors:  S P Master; J F Taylor; S K Kyalwazi; J L Ziegler
Journal:  Br Med J       Date:  1970-03-07

4.  Disseminated visceral Kaposi's sarcoma. Appearance after human renal homograft operation.

Authors:  J H Siegel; R Janis; J C Alper; H Schutte; L Robbins; M D Blaufox
Journal:  JAMA       Date:  1969-02-24       Impact factor: 56.272

5.  Herpes-type virus particles in tissue culture of Kaposi's sarcoma from different geographic regions.

Authors:  G Giraldo; E Beth; F Haguenau
Journal:  J Natl Cancer Inst       Date:  1972-12       Impact factor: 13.506

6.  Treatment of Kaposi's sarcoma with actinomycin-D and cyclophosphamide: results of a randomized clinical trial.

Authors:  C L Vogel; C J Templeton; A C Templeton; J F Taylor; S K Kyalwazi
Journal:  Int J Cancer       Date:  1971-07-15       Impact factor: 7.396

7.  Lymphocyte transformation in patients with Kaposi's sarcoma.

Authors:  J F Taylor; U Junge; L Wolff; F Deinhardt; S K Kyalwazi
Journal:  Int J Cancer       Date:  1971-11-15       Impact factor: 7.396

Review 8.  Kaposi's sarcoma: a clinicopathologic study with particular reference to its relationship to the reticuloendothelial system.

Authors:  W A Reynolds; R K Winkelmann; E H Soule
Journal:  Medicine (Baltimore)       Date:  1965-09       Impact factor: 1.889

9.  Delayed cutaneous hypersensitivity reactions to autologous extracts of Burkitt-lymphoma cells.

Authors:  L Fass; R B Herberman; J Ziegler
Journal:  N Engl J Med       Date:  1970-04-02       Impact factor: 91.245

10.  Immunologic responses in cancer patients.

Authors:  A C Solowey; F T Rapaport
Journal:  Surg Gynecol Obstet       Date:  1965-10
  10 in total
  5 in total

1.  [Cutaneous nodular Kaposi sarcoma following kidney transplantation and immunosuppression].

Authors:  C Luderschmidt; G Hillebrand; L A Castro; C Hammer
Journal:  Klin Wochenschr       Date:  1984-09-03

2.  Disentangling Kaposi's sarcoma.

Authors: 
Journal:  Br Med J       Date:  1978-10-14

3.  Vitiligo associated with Kaposi's sarcoma.

Authors:  G A Alexander
Journal:  J Natl Med Assoc       Date:  1982-02       Impact factor: 1.798

4.  Growth kinetics of Kaposi's sacroma.

Authors:  J F Taylor; O H Iversen; R Bjerknes
Journal:  Br J Cancer       Date:  1977-04       Impact factor: 7.640

5.  Neurological complications of Kaposi's sarcomat. An analysis of 5 cases and a review of the literature.

Authors:  N W Barton; B Safai; S L Nielsen; J B Posner
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.